Clinical Trials Using Trametinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trametinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-36 of 36

  • Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

    This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Trametinib, dabrafenib, encorafenib, and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib may work better in treating patients with BRAF-mutated melanoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Trametinib in Treating Patients with Progressive Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well trametinib works in treating patients with castration-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Next Generation Personalized Neuroblastoma Therapy with Ribociclib and Ceritinib, Trametinib, or HDM2 Inhibitor HDM201 in Treating Younger Patients with High-Risk Neuroblastoma

    This phase I trial studies the side effects and best dose of ribociclib when given together with ceritinib, and HDM2 inhibitor HDM201, and to also see how well ribociclib and ceritinib, trametinib, or HDM2 inhibitor HDM201 work in treating patients with high-risk neuroblastoma. Ribociclib, ceritinib, trametinib, and HDM2 inhibitor HDM201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Assigning patients to different treatment groups with ribociclib and ceritinib, trametinib, or HDM2 inhibitor HDM201 based on genetic testing may work better in treating neuroblastoma.
    Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

  • Dabrafenib Mesylate, Trametinib, and 6 Melanoma Helper Peptide Vaccine in Treating Patients with Stage IIIB-IV Melanoma

    This phase I / II trial studies the side effects and how well dabrafenib mesylate, trametinib, and 6 melanoma helper peptide vaccine work in treating patients with stage IIIB-IV melanoma. Dabrafenib mesylate and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines, such as 6 melanoma helper peptide vaccine, made from peptides derived from melanoma proteins, may help the body build an effective immune response to kill tumor cells that express melanoma-specific antigens. Giving dabrafenib, trametinib, and 6 melanoma helper peptide vaccine may work better in treating patients with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Dabrafenib and Trametinib before and after Surgery in Treating Patients with Stage IIIB-C Melanoma with BRAF V600 Mutation

    This is a single arm phase II trial focused on how dabrafenib and trametinib before and after surgery works in treating patients with stage IIIB-C melanoma that has a specific mutation in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving dabrafenib and trametinib after surgery may kill any remaining tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Trametinib in Increasing Tumoral Iodine Incorporation in Patients with Recurrent or Metastatic Thyroid Cancer

    This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors

    This phase Ib / II trial studies the side effects and best dose of trametinib and navitoclax and how well they work in treating patients with solid tumors that have spread to other places in the body (advanced or metastatic). Trametinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • A Study of Select Drug Combinations in Adult Patients With Advanced / Metastatic BRAF V600 Colorectal Cancer

    A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Trametinib in Treating Patients with Advanced Cancer with or without Hepatic Dysfunction

    This phase I trial studies the side effects and best dose of trametinib in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) with or without liver (hepatic) dysfunction. Trametinib may stop the growth of tumor cells by blocking proteins needed for cell growth. When these proteins are blocked, the growth of cancer cells may be stopped and the cancer cells will then die. Hepatic dysfunction is frequently found in patients with advanced cancer and usually prevents patients from receiving standard treatments or from participating in clinical trials. Patients may also need dose adjustments or absorb drugs differently. Trametinib may be a better treatment for patients with advanced cancers and hepatic dysfunction.
    Location: 6 locations

  • Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

    Background: Bile duct cancer is cancer of the slender tubes of the biliary tract. These tubes carry bile through the liver. Such cancer tumors often have an abnormal or mutated gene. Researchers think a mix of drugs can slow the progression of gene-mutated cancers of the biliary tract. Objective: To see if using a combination of trametinib and hydroxychloroquine (HCQ) increases the period of time it takes for a person s bile tract carcinoma (BTC) to get worse. Eligibility: Adults age 18 and older with BTC. Design: Participants will be screened with a physical exam, medical history, and cancer history. Their ability to do their normal activities will be assessed. They will have blood and urine tests. They will give a tumor sample. They will have heart tests. They may talk with a heart doctor. They may have an eye exam. They may have a tuberculosis test. They will have computer tomography (CT) scans of the chest, abdomen, and pelvis. They may have magnetic resonance imaging (MRI) scans of the chest, abdomen, pelvis. Participants will repeat some screening tests throughout the study. Participants will take HCQ and trametinib tablets by mouth daily in 28-day cycles. They will have study visits once a month. They will take the drugs until they have bad side effects or the drugs stop working. Participants will have one more tumor biopsies during the treatment. They will have blood taken often. One month after treatment ends, participants will have a safety follow-up visit. Then they will be called or emailed every 6 months for the rest of their life.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas

    This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with low grade gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low grade gliomas compared to trametinib or everolimus alone.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California